Back to Results
First PageMeta Content
Angiotensin II receptor antagonists / Novartis / Pharmaceuticals policy / False Claims Act / Pharmaceutical industry / TennCare / Medicaid / Valsartan / Tegaserod / Chemistry / Organic chemistry / Pharmacology


Major Drug Manufacturer Novartis to Pay $422.5 Million to Settle Claims of Off-Label Drug Marketing and Kickbacks
Add to Reading List

Document Date: 2011-07-20 17:30:31

Open Document

File Size: 294,42 KB

Share Result on Facebook

Company

Novartis Pharmaceuticals Corporation / /

Currency

USD / /

Event

FDA Phase / /

Facility

United States District Court / /

IndustryTerm

treatment of bipolar disorder / drug manufacturer / /

MedicalCondition

partial seizures / pain / epilepsy / bipolar disorder / /

Organization

federal government / Food and Drug Administration / National Association of Medicaid Fraud Control Units / Medicaid Fraud Control Unit / United States District Court for the Eastern District of Pennsylvania / Tennessee Bureau of Investigation / United States Department of Health and Human Services / office of the Inspector General / /

Person

Robert E. Cooper / Jr. / Mark Gwyn / Bob Cooper / Trileptal / Sharon Curtis-Flair / /

/

Position

News Release Attorney General / Director / speaker / Attorney General / /

Product

Diovan / Zelnorm / Sandostatin / Exforge / Trileptal / Tekturna / LABEL DRUG / OFF-LABEL DRUG / /

ProvinceOrState

Tennessee / New Jersey / Pennsylvania / Florida / /

SocialTag